![Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review - ScienceDirect Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1477513122003795-gr2.jpg)
Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review - ScienceDirect
![Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study | Scientific Reports Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-23795-5/MediaObjects/41598_2022_23795_Fig1_HTML.png)
Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study | Scientific Reports
![Efficacy and Safety of 10 mg Solifenacin Succinate in Patients with Overactive Bladder Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Pivotal Trial - Fred E Govier, Neila Smith, Takeshi Uchida, Efficacy and Safety of 10 mg Solifenacin Succinate in Patients with Overactive Bladder Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Pivotal Trial - Fred E Govier, Neila Smith, Takeshi Uchida,](https://journals.sagepub.com/cms/10.4137/CMU.S4960/asset/images/large/10.4137_cmu.s4960-fig2.jpeg)
Efficacy and Safety of 10 mg Solifenacin Succinate in Patients with Overactive Bladder Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Pivotal Trial - Fred E Govier, Neila Smith, Takeshi Uchida,
![Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies - ScienceDirect Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S147751311930436X-fx1.jpg)